Lanreotide (diTFA)

• UNSPSC Description:

  Lanreotide (BIM 23014) diTFA is a somatostatin analogue with antineoplastic activity. Lanreotide diTFA can be used for the research of carcinoid syndrome[1][2].

• Target Antigen:

  Others

• Type:

  Peptides

• Related Pathways:

  Others

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Cancer; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/lanreotide-ditfa.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C([C@@H](NC([C@@](CSSC[C@@H](C(N[C@H](C(N)=O)[C@H](O)C)=O)NC([C@H](C(C)C)NC([C@@](CCCCN)([H])NC1=O)=O)=O)([H])NC([C@H](N)CC2=CC3=CC=CC=C3C=C2)=O)=O)CC4=CC=C(O)C=C4)N[C@@H]1CC5=CNC6=C5C=CC=C6.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O

• Molecular Weight:

  1324.37

• References & Citations:

  [1]Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16(3):1045-55.|[2]Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf). 2003 Jul;59(1):115-28.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  1024499-83-9